DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.ECCO'24Year: 2024
Authors: Malham, M.(1);Jansson, S.(1)*;Ingels, H.A.S.(2);Jørgensen, M.H.(3);Roed, N.(4);Wewer, A.V.(5);Fox, M.P.(6);
(1)Amager Hvidovre Hospital and Copenhagen IBD Center- University of Copenhagen-, Department of Pediatrics and Adolescent Medicine, Hvidovre, Denmark;(2)Amager Hvidovre Hospital and Copenhagen IBD Center- University of Copenhagen-, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark;(3)Rigshospitalet- University of Copenhagen, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark;(4)University of Copenhagen- Copenhagen, Section of Epidemiology- Department of Public Health, Copenhagen, Denmark;(5)Copenhagen IBD Center- Amager Hvidovre Hospital- University of Copenhagen, Department of Pediatrics and Adolescent Medicine, Hvidovre, Denmark;(6)Boston University School of Public Health, Departments of Epidemiology and Global Health, Boston, United States;
DOP64: Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trialECCO'24Year: 2024
Authors: Raine, T.(1)*;Danese, S.(2);Schreiber, S.(3);Gao, X.(4);Hanauer, S.(5);Torres, J.(6);Kligys, K.(7);Huang, X.(7);Neimark, E.(7);Anschutz, T.(7);Crowley, J.(7);Cross, R.K.(8);
(1)Addenbrooke’s Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)IRCCS Ospedale San Raffaele Hospital and Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(3)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(4)The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(5)Northwestern University, Division of Gastroenterology, Chicago, United States;(6)Hospital Beatriz Ângelo- Universidade de Lisboa- and Hospital da Luz, Division of Gastroenterology, Lisbon, Portugal;(7)AbbVie Inc., Research and Development, North Chicago, United States;(8)University of Maryland School of Medicine, Department of Medicine, Baltimore, United States;
DOP65: Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trialECCO'24Year: 2024
Authors: Amiot, A.(1)*;Seksik, P.(2);Meyer, A.(3);Stefanescu, C.(4);Wils, P.(5);Altwegg, R.(6);Vuitton, L.(7);Plastaras, L.(8);Nicolau, A.(9);Buisson, A.(10);Duveau, N.(11);Laharie, D.(12);Boualit, M.(13);Allez, M.(14);Coffin, B.(15);Chanteloup, E.(16);Bouguen, G.(17);Vicaut, E.(18);Peyrin-Biroulet, L.(19);
(1)Bicetre Hospital- Paris Saclay University, Department of Gastroenterology, Le Kremlin Bicêtre, France;(2)CHU Saint Antoine, Gastroenterology, Paris, France;(3)CHU Bicetre, Gastroenterology, Le Kremlin Bicetre, France;(4)CHU Beaujon, Gastroenterology, Clichy, France;(5)CHRU Lille, Gastroenterology, Lille, France;(6)CHU Montpellier, Gastroenterology, Montpellier, France;(7)CHU Besancon, Gastroenterology, Besancon, France;(8)CHR Colmar, Gastroenterology, Colmar, France;(9)CHU Nice, Gastroenterology, Nice, France;(10)CHU Clermont ferrand, Gastroenterology, Clermont Ferrand, France;(11)CH Roubaix, Gastroenterology, Roubaix, France;(12)CHU Bordeaux, Gastroenterology, Bordeaux, France;(13)CH Valenciennes, Gastroenterology, Valenciennes, France;(14)CHU Saint Louis, Gastroenterology, Paris, France;(15)CHU Louis Mourier, Gastroenterology, Colombes, France;(16)CH Saint Joseph, Gastroenterology, Paris, France;(17)CHU Rennes, Gastroenterology, Rennes, France;(18)CHU Fernand Vidal, Clinical research unit, paris, Cambodia;(19)CHRU Nancy, Gastroenterology, Nancy, France;ACTIVE study group
DOP66: INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulasECCO'24Year: 2024
Authors: Fathallah, N.(1)*;Zmora, O.(2);Baumgart, D.C.(3);Faubion, W.(4);Ferrante, M.(5);Gecse, K.(6);Wright, E.(7);McKay, C.(8);Ren, K.(9);Punchard, M.(10);Zhang, B.(11);Panés, J.(12);
(1)Hospital Paris Saint-Joseph-, Coloproctology, Paris, France;(2)Shamir Medical Center, Department of Surgery, Tel Aviv, Israel;(3)University of Alberta, Division of Gastroenterology, Edmonton AB, Canada;(4)Mayo Clinic, Gastroenterology and Hepatology, Rochester MN, United States;(5)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(6)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;(7)Takeda Pharmaceuticals USA Inc., Global Medical Affairs, Cambridge MA, United States;(8)Takeda Pharmaceuticals USA Inc., Global Evidence and Outcomes, Cambridge MA, United States;(9)Takeda Pharmaceuticals USA Inc., Data Sciences Institute, Cambridge MA, United States;(10)ICON, Clinical Operations, Madrid, Spain;(11)Takeda Pharmaceuticals USA Inc., GI Medical Safety, Cambridge MA, United States;(12)Hospital Clinic de Barcelona- IDIBAPS- CIBERehd, Inflammatory Bowel Disease Unit, Barcelona, Spain;
DOP67: MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative ColitisECCO'24Year: 2024
Authors: Villemin, C.(1);Schreiber, F.(1);Bakdash, G.(1);Rimington, O.(1);McCluskey, S.(1);Neville, A.(1);Robinson, M.(1);Birrell, C.(2);Wilkinson, A.(1);Carter, R.(2)*;Lawley, T.(1);
(1)Microbiotica, Pre-Clinical Development, Cambridge, United Kingdom;(2)Microbiotica, Clinical Development, Cambridge, United Kingdom;
DOP68: Natural history of isolated Crohn@E@s Disease perianal fistulaECCO'24Year: 2024
Authors: Sangmo, L.(1)*;Quraishi, B.(2);Rajauria, P.(3);Colombel, J.F.(4);Ungaro, R.(5);Wong, S.Y.(5);
(1)Icahn School of Medicine at Mount Sinai, Internal Medicine, New York, United States;(2)Mount Sinai Beth Israel, Internal Medicine, New York City, United States;(3)Icahn School of Medicine at Mount Sinai, Gatroenterology, New York City, United States;(4)Icahn School of Medicine at Mount Sinai, Internal Medicine, New York City, United States;(5)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States;
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker studyECCO'24Year: 2024
Authors: Gacesa, R.(1,2)*;Klaassen, M.A.Y.(1,2,3,4);Collij, V.(1,2);Björk, J.R.(1,2);Blankenstein, A.D.(1);Jansen, B.H.(1);Dijkstra, G.(1);Visschedijk, M.(1);Festen, E.A.M.(1);Ananthakrishnan, A.(3,5);Alm, E.(4,6);Weersma, R.K.(1);
(1)University Medical Center Groningen, Dept. of Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Dept. of Genetics, Groningen, The Netherlands;(3)Massachusetts General Hospital, Center for Crohns and Colitis, Boston, United States;(4)Massachusetts Institute of Technology, Department of Biological Engineering, Boston, United States;(5)Harvard University, Harvard Medical School, Boston, United States;(6)Harvard University and Massachusetts Institute of Technology, Broad Institute, Boston, United States;
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) SurveyECCO'24Year: 2024
Authors: Dubinsky, M.C.(1)*;Gibble, T.(2);Travis, S.(3);Panaccione, R.(4);Hibi, T.(5);Bleakman, A.P.(2);Panni, T.(2);Kayhan, C.(2);Favia, A.D.(2); Atkinson, C.(6);Schreiber, S.(7);Rubin, D.T.(8);
(1)Icahn School of Medicine, Medicine - Gastroenterology, New York, United States;(2)Eli Lilly and Company, Immunology, Indianapolis, United States;(3)University of Oxford, Gastroenterology, Oxford, United Kingdom;(4)University of Calgary, Gastroenterology, Alberta, Canada;(5)Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(6)Adelphi Real World, Statistics, Bollington, United Kingdom;(7)University Hospital Schleswig-Holstein, Clinic for Internal Medicine, Kiel, Germany;(8)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology- Hepatology and Nutrition, Chicago, United States;
DOP71: Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment doseECCO'24Year: 2024
Authors: Vermeire, S.(1)*;Danese, S.(2);Peyrin-Biroulet, L.(3);Dubinsky, M.(4);Dulai, P.(5);Tilg, H.(6);Siegmund, B.(7);Sloan, S.(8);Gineste, P.(8);Rabbat, C.(9);Sands, B.E.(10);
(1)University hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(2)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)CHU de Nancy Université de Lorraine, Service de Gastroentérologie, Nancy, France;(4)Icahn School of Medicine Mount Sinai, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic, New York, United States;(5)Feinberg School of Medicine Northwestern University, Division of Gastroenterology and Hepatology, Chicago, United States;(6)Medical University Innsbruck, Department of Internal Medicine- Gastroenterology- Hepatology- & Endocrinology, Innsbruck, Austria;(7)Charité- Universitätsmedizin, Medizinische Klinik m. S. Gastroenterologie- Infektiologie und Rheumatologie, Berlin, Germany;(8)Abivax, Clinical Operations, Paris, France;(9)Abivax, Medical Affairs, Paris, France;(10)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
DOP72: Pregnancy for IBD-patients with an enterostomy is feasible but is associated with complicationsECCO'24Year: 2024
Authors: Bouwknegt, D.(1)*;van der Weide, A.H.C.(1);Dijkstra, G.(1);van Dop, W.(2);Prins, J.R.(3);Hoogenboom, F.J.(4);van der Woude, C.J.(5);Visschedijk, M.C.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)University Medical Center Groningen, Obstetrics and Gynaecology, Groningen, The Netherlands;(4)University Medical Center Groningen, Abdominal Surgery, Groningen, The Netherlands;(5)Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, The Netherlands;Dutch Initiative on Crohn and Colitis (ICC)
DOP73: Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohortECCO'24Year: 2024
Authors: VerstocktMSc. PhD, S.(1)*;Glorieus, E.(2);De Wolf, M.(3);Lenfant, M.(1);Barbaraci, M.(3);Sabino, J.(4);Ferrante, M.(4);Geldof, J.(2);Verstockt, B.(4);Laukens, D.(5);Cleynen, I.(6);Vandermeulen, L.(3);Lobaton, T.(2);Vermeire, S.(4);
(1)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(2)University Hospital of Ghent, Department of Gastroenterology, Ghent, Belgium;(3)University Hospital of Brussels, Department of Gastroenterology, Brussels, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(6)KU Leuven, Department of Human Genetics, Leuven, Belgium;
DOP74: Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES studyECCO'24Year: 2024
Authors: Chaparro, M.(1)*;Hermida, S.(1);Acosta, D.(1);Fernández-Clotet, A.(2);Barreiro-de Acosta, M.(3);Hernández Martínez, Á.(4);Arroyo, M.(5);Bosca-Watts, M.M.(6);Diz-Lois Palomares, M.T.(7);Menchén, L.(8);Martínez Cadilla, J.(9);Leo-Carnerero, E.(10);Muñoz Villafranca, C.(11);Sierra-Ausín, M.(12);González, Y.(13);Riestra, S.(14);Sendra Rumbeu, P.(15);Cabello Tapia, M.J.(16);García de la Filia, I.(17);Montil Miguel, E.(18);Ceballos, D.(19);Pajares Villarroya, R.(20);Ramírez de la Piscina, P.(21);Martín-Arranz, M.D.(22);Ramos, L.(23);Ruiz-Cerulla, A.(24);Teresa de Jesús , M.P.(25);San Miguel, E.(26);Calvet, X.(27);Huguet, J.M.(28);Keco-Huerga, A.(29);Lorente Poyatos, R.H.(30);Muñoz, J.F.(31);Ponferrada, Á.(32);Sicilia Aladrén, B.(33);Delgado-Guillena, P.(34);Gómez Delgado, E.(35);Rancel-Medina, F.J.(36);Alonso-Galán, H.(37);P. Gisbert, J.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Department, Madrid, Spain;(2)Hospital Clinic of Barcelona- Institut d´Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBERehd, Gastroenterology Department, Barcelona, Spain;(3)Complejo Hospitalario Universitario de Santiago- Santiago de Compostela, Gastroenterology Department, Santiago de Compostela, Spain;(4)Hospital Universitario Torrecárdenas, Gastroenterology Department, Almería, Spain;(5)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Department, Zaragoza, Spain;(6)Hospital Clínico Universitario de Valencia, Gastroentetology Department, Valencia, Spain;(7)Complejo Hospitalario Universitario A Coruña, Gastroenterology Department, A Coruña, Spain;(8)Hospital General Universitario Gregorio Marañón, Gastroenterology Department, Madrid, Spain;(9)Hospital Álvaro Cunqueiro, Gastroenterology Department, Vigo, Spain;(10)Hospital Universitario Virgen del Rocio, Gastroenterology Department, Sevilla, Spain;(11)Hospital Universitario de Basurto, Gastroenterology Department, Bilbao, Spain;(12)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(13)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Department, Madrid, Spain;(14)Hospital Universitario Central de Asturias, Gastroenterology Department, Oviedo, Spain;(15)Hospital Universitario Son Espases, Gastroenterology Department, Palma de Mallorca, Spain;(16)Hospital Universitario Virgen de las Nieves, Gastroenterology Department, Granada, Spain;(17)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(18)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(19)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Department, Las Palmas de Gran Canaria, Spain;(20)Hospital Universitario Infanta Sofía, Gastroenterology Department, Madrid, Spain;(21)Hospital Universitario de Araba, Gastroenterology Department, Álava, Spain;(22)La Paz University Hospital. School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute for Health Research- La Paz Hospital, Gastroenterology Department, Madrid, Spain;(23)Complejo Hospitalario Universitario de Canarias, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(24)Hospital Universitario de Bellvitge, Gastroenterology Department, L´Hospitalet de Llobregat- Barcelona, Spain;(25)Hospital Virgen de la Luz, Gastroenterology Department, Cuenca, Spain;(26)Hospital Universitario de Getafe, Gastroenterology Department, Madrid, Spain;(27)Parc Taulí- Hospital Universitari. Institutd’Investigació i Innovació Parc Taulí I3PT-CERCA. Universitat Autònoma de Barcelona. Centro de Investigación Biomédica En Red de enfermedades hepáticas y digestivas CIBERehd. Instituto de Salud Carlos III, Gastroenterology Department, Sabadell, Spain;(28)Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(29)Hospital de Valme, Gastroenterology Department, Sevilla, Spain;(30)Hospital General Universitario de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(31)Hospital Universitario de Salamanca, Gastroenterology Department, Salamanca, Spain;(32)Hospital Universitario Infanta Leonor, Gastroenterology Department, Madrid, Spain;(33)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(34)Hospital de Mérida, Gastroenterology Department, Mérida, Spain;(35)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Department, Huelva, Spain;(36)Hospital Río Carrión- Complejo Asistencial de Palencia CAUPA, Gastroenterology Department, Palencia, Spain;(37)Hospital Universitario Donostia- Instituto Instituto Biogipuzkoa, Gastroenterology Department, San Sebastián, Spain;on behalf of ULISES study group
DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24Year: 2024
Authors: Rubín De Célix, C.(1)*;Ricart, E.(2);Martín-Arranz, M.D.(3);Pérez-Martínez, I.(4);Barrio, J.(5);Mesonero, F.(6);Gomollón, F.(7);de Castro, L.(8);Ramos, L.(9);García-López, S.(10);Arias, L.(11);Mañosa, M.(12);Iglesias, E.(13);Calvet, X.(14);Pascual, I.(15);Casanova, M.J.(1);Pérez-Calle, J.L.(16);Giordano, A.(17);Sierra, M.(18);Vera, I.(19);Navarro-Llavat, M.(20);Lorente, R.(21);Piqueras, M.(22);Rivero, M.(23);Guardiola, J.(24);Esteve, M.(25);Fuentes Coronel, A.(26);Rodríguez-Lago, I.(27);Ponferrada, Á.(28);Ber, Y.(29);Tardillo, C.(30);Márquez, L.(31);Carpio, D.(32);Taxonera, C.(33);Bermejo, F.(34);Busquets, D.(35);Camps, B.(36);Domènech, E.(12);Chaparro*, M.(1);Gisbert*, J.P.(1);
(1)Gastroenterology Department, Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(2)Gastroenterology Department, Hospital Clínic i Provincial- Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Barcelona, Spain;(3)Gastroenterology Department, Hospital Universitario de La Paz, Madrid, Spain;(4)Gastroenterology Department, Hospital Universitario Central de Asturias and ISPA, Asturias, Spain;(5)Gastroenterology Department, Hospital Río Hortega, Valladolid, Spain;(6)Gastroenterology Deparment, Hospital Universitario Ramón y Cajal, Madrid, Spain;(7)Gastroenterology Department, Hospital Clínico Lozano Blesa- Instituto de investigación sanitaria de Aragón IIS- and CIBEREHD, Zaragoza, Spain;(8)Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain;(9)Gastroenterology Department, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain;(10)Gastroenterology Department, Hospital Universitario Miguel Servet and IIS, Zaragoza, Spain;(11)Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain;(12)Gastroenterology Department, Hospital Universitario Germans Trias i Pujol and CIBEREHD, Badalona, Spain;(13)Gastroenterology Department, Hospital Reina Sofía- IMIBIC and UCO, Córdoba, Spain;(14)Gastroenterology Department, Hospital Universitari Parc Taulí- Institut d@E@Investigació i Innovació Parc Taulí- Departament de Medicina- Universitat Autònoma de Barcelona- and CIBEREHD, Barcelona, Spain;(15)Gastroenterology Department, Hospital Clínico de Valencia, Valencia, Spain;(16)Gastroenterology Department, Hospital Universitario de Alcorcón, Madrid, Spain;(17)Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;(18)Gastroenterology Department, Complejo Asistencial Universitario de León, León, Spain;(19)Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain;(20)Gastroenterology Department, Hospital Moisès Broggi, Sant Joan Despí, Spain;(21)Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain;(22)Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain;(23)Gastroenterology Department, Hospital Universitario Marqués de Valdecilla and IDIVAL, Santander, Spain;(24)Gastroenterology Department, Hospital Universitari Bellvitge, L@E@Hospitalet de Llobregat, Spain;(25)Gastroenterology Department, Hospital Universitari Mútua Terrassa- University of Barcelona- and CIBEREHD, Barcelona, Spain;(26)Gastroenterology Department, Complejo Asistencial de Zamora, Zamora, Spain;(27)Gastroenterology Department, Hospital Universitario de Galdakao, Bilbao, Spain;(28)Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain;(29)Gastroenterology Department, Hospital de San Jorge, Huesca, Spain;(30)Gastroenterology Department, Hospital Universitario Nuestra Sra. de la Candelaria, Santa Cruz de Tenerife, Spain;(31)Gastroenterology Department, Hospital del Mar and Institut Hospital del Mar d@E@Investigacions Mèdiques IMIM, Barcelona, Spain;(32)Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain;(33)Gastroenterology Department, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos IdISSC, Madrid, Spain;(34)Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain;(35)Gastroenterology Department, Hospital Dr. Josep Trueta, Girona, Spain;(36)Gastroenterology Department, Hospital General de Granollers, Barcelona, Spain;on behalf of the ENEIDA project of GETECCU *Co-senior authorship
DOP76: Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studiesECCO'24Year: 2024
Authors: Tinoco da Silva Torres, J.(1)*;Panés, J.(2);Siegel, C.A.(3);Dubinsky, M.C.(4);Dulai, P.S.(5);Tanida, S.(6);Danese, S.(7);Levine, P.(8);Lai, J.H.(9);Sharma, D.(8);Shukla, N.(8);Remple, V.(8);Hecht, P.M.(8);Sanchez Gonzalez, Y.(8);Panaccione, R.(10);
(1)Hospital Beatriz Ângelo- Hospital da Luz- and Faculdade de Medicina- Universidade de Lisboa, Gastroenterology Division, Loures, Portugal;(2)Hospital Clínic Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(3)Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology- Inflammatory Bowel Disease Center, Lebanon, United States;(4)Icahn School of Medicine at Mount Sinai, Dr Henry D. Janowitz Division of Gastroenterology, New York, United States;(5)Northwestern University, Department of Medicine- Division of Gastroenterology and Hepatology, Chicago, United States;(6)University Graduate School of Medical Sciences- 1 Kawasumi- Mizuho-cho- Mizuho-ku, Education and Research Center for Community Medicine- Nagoya City, Nagoya, Japan;(7)San Raffaele University, Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and Vita-Salute, Milan, Italy;(8)AbbVie Inc., none, North Chicago, United States;(9)AbbVie Inc and Health Outcomes Division- College of Pharmacy- The University of Texas at Austin, none, Austin, United States;(10)Inflammatory Bowel Disease Clinic, none, Calgary, Canada;
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case seriesECCO'24Year: 2024
Authors: Pronk, A.(1)*;Beek, K.J.(2);Wildenberg, M.E.(3);Bemelman, W.A.(1);Stoker, J.(2);Buskens, C.J.(1);
(1)Amsterdam University Medical Centers, Surgery, Amsterdam, The Netherlands;(2)Amsterdam University Medical Centers, Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Tytgat Institute for Liver and Intestinal Research- Amsterdam University Medical Centers, Gastroenterology and Hepatology, Amsterdam, The Netherlands;
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North studyECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Feagan, B.G.(2);Sands, B.E.(3);Rieder, F.(4);Torres, J.(3,5,6,7);Liu, Z.(8);Jain, A.(8);Poehler, A.M.(9);Wu, H.(8);Osterman, M.T.(8);Abreu, M.T.(10);Dulai, P.S.(11);
(1)Department of Internal Medicine I- University Hospital Schleswig-Holstein- Kiel University, Internal Medicine I, Kiel, Germany;(2)Robarts Research Institute- Western University, Gastroenterology, London, Canada;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Department of Gastroenterology- Hepatology- and Nutrition- Digestive Disease Institute- Cleveland Clinic, Gastroenterology- Hepatology- and Nutrition, Cleveland, United States;(5)Division of Gastroenterology- Hospital da Luz, Gastroenterology, Lisbon, Portugal;(6)Division of Gastroenterology- Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal;(7)Faculdade de Medicina- Universidade de Lisboa, Gastroenterology, Lisbon, Portugal;(8)Bristol Myers Squibb, n/a, Princeton, United States;(9)Bristol Myers Squibb, n/a, Munich, Germany;(10)University of Miami Miller School of Medicine, Gastroenterology, Miami, United States;(11)Feinberg School of Medicine- Northwestern University, Gastroenterology and Hepatology, Chicago, United States;
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohortECCO'24Year: 2024
Authors: Verstockt., B.(1,2)*;Taelman, T.(1);Vavricka, S.R.(3);Zabana, Y.(4);Lenfant, M.(1);Macaigne, G.(5);Maillard, M.H.(6,7);Savarino, E.(8);Teich, N.(9);Kiudelis, V.(10);de la Revilla Negro, J.(11);Ribaldone, D.G.(12);Barreiro-de Acosta, M.(13);Wildt, S.(14);Rivière, P.(15);Fumery, M.(16);Truyens, M.(17);Amiot, A.(18);Marsal, J.(19);Levartovsky, A.(20);Vieujean, S.(21);Somers, M.(22);Cremer, A.(23);Lutakov, I.(24);Cohen, N.A.(25);Dewit, S.(26);Bajer, L.(27);Rahier, J.F.(28);Backman, A.S.(29,30);Nancey, S.(31);Choden, T.(32);Van Dongen, J.(33);Münch, A.(34);Julsgaard, M.(35,36);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(3)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;(4)ospital Universitari Mútua Terrassa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Centre Hospitalier de Marne-la-Vallee, Hepatogastroenterology Unit, Jossigny, France;(6)Lausanne Digestive Disease Center, Gastroenterology, Lausanne, Switzerland;(7)Lausanne University Hospital, Service of Gastroenterology and Hepatology, Lausanne, Switzerland;(8)University of Padua, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(9)Internistische Gemeinschaftspraxis, Gastroenterology, Leipzig, Germany;(10)Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Department of Gastroenterology, Kaunas, Lithuania;(11)Addenbrookes Hospital. Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(12)University of Turin, Department of Medical Sciences, Turin, Italy;(13)University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(14)Hvidovre Hospital- University Hospital of Copenhagen, Gastrounit, Copenhagen, Denmark;(15)CHU de Bordeaux, Service d’hépato-gastroentérologie et oncologie digestive, Bordeaux, France;(16)Amiens University Hospital, Department of gastroenterology, Amiens, France;(17)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(18)Bicetre university hospital- Paris Saclay university, Department of gastroentérology, le Kremlin Bicêtre, France;(19)Skane University Hospital, Department of Gastroenterology, Lund, Sweden;(20)Sheba Medical Center, Department of Gastroenterology, Tel-Hashomer, Israel;(21)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(22)University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium;(23)Erasme University Hospital, Department of Gastroenterology and Hepatology, Brussels, Belgium;(24)University Hospital “Queen Joanna-ISUL” Sofia- Medical University Sofia, Clinical Center of Gastroenterology, Sofia, Bulgaria;(25)Tel Aviv Medical Center, IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(26)Noorderhart Mariaziekenhuis, Department of Gastroenterology, Pelt, Belgium;(27)Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology, Prague, Czech Republic;(28)Université catholique de Louvain- CHU UCL Namur, Department of Gastroenterology and Hepatology, Yvoir, Belgium;(29)Ersta Hospital, Department of Internal Medicine, Stockholm, Sweden;(30)Huddinge- Karolinska Institutet, Unit of gastroenterology-Department of Medicine, Stockholm, Sweden;(31)Lyon-Sud hospital- Hospices Civils de Lyon, Department of Gastroenterology, Pierre-Bénite, France;(32)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(33)AZ Sint Maarten, Department of Gastroenterology, Mechelen, Belgium;(34)Linköping University, Department of Gastroenterology and Hepatology, Linköping, Sweden;(35)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(36)Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Aalborg University, Department of Clinical Medicine, Copenhagen, Denmark;
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO RegistryECCO'24Year: 2024
Authors: Chaparro, M.(1)*;García Donday, M.(1);Núñez Ortiz, A.(2);Calviño Suarez, C.(3);Rubio Iturria, S.(4);Sánchez Azofra, M.(5);Calvo Moya, M.(6);Pérez-Martínez, I.(7);Fernández-Clotet, A.(8);Alfambra, E.(9);Marín Pedrosa, S.(10);Diz-Lois Palomares, M.T.(11);Hernandez, V.(12);Ruiz-Cerulla, A.(13);Casanova, M.J.(1);Rivero, M.(14);Huguet, J.M.(15);Vicente Lidón, R.(16);Árias García, L.(17);Guerra, I.(18);Hervías Cruz, D.(19);Gutiérrez Casbas, A.(20);Bejarano, A.(21);Camargo Camero, R.(22);Rodríguez-Lago, I.(23);Aguas, M.(24);De Jorge Turrión, M.Á.(25);Masedo Gonzalez, Á.(26);López Serrano, P.(27);Valldosera Gomis, G.(28);Ceballos, D.(29);Bujanda, L.(30);Molina Arriero, G.(31);Vega Villaamil, P.(32);Van Domselaar , M.(33);Boscá Watts, M.M.(34);Lucendo, A.J.(35);Zúñiga de Mora-Figueroa, B.(36);Busquets, D.(37);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Department, Madrid, Spain;(2)Hospital Universitario Virgen del Rocío, Gastroenterology Department, Sevilla, Spain;(3)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Department, Santiago de Compostela, Spain;(4)Hospital Universitario de Navarra, Gastroenterology Department, Navarra, Spain;(5)Hospital Universitario La Paz. Grupo de enfermedades inmunomediadas gastrointestinales y otras patologías digestivas. Instituto de Investigación Sanitaria del Hospital Universitario La Paz – IdiPAZ., Gastroenterology Department, Madrid, Spain;(6)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Department, Majadahonda, Spain;(7)Hospital Universitario Central de Asturias. Diet- Microbiota and Health Group. Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Department, Oviedo, Spain;(8)Hospital Universitario Clinic I Provincial. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas CIBERehd. Institut d@E@Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Department, Barcelona, Spain;(9)Hospital Clínico Universitario Lozano Blesa. Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón, Gastroenterology Department, Zaragoza, Spain;(10)Hospital Universitario Reina Sofía de Córdoba, Gastroenterology Department, Córdoba, Spain;(11)Complexo Hospitalario Universitario de A Coruña, Gastroenterology Department, A Coruña, Spain;(12)Hospital Álvaro Cunqueiro. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS-UVIGO., Gastroenterology Department, Vigo, Spain;(13)Hospital Universitario de Bellvitge, Gastroenterology Department, L’Hospitalet de Llobregat., Spain;(14)Hospital Universitario Marqués de Valdecilla e Instituto de Investigación IDIVAL, Gastroenterology Department, Santander, Spain;(15)Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(16)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(17)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(18)Hospital Universitario de Fuenlabrada e Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Department, Madrid, Spain;(19)Hospital General de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(20)Hospital General Universitario Dr Balmis de Alicante- ISABIAL. CIBEREHD, Gastroenterology Department, Alicante, Spain;(21)Hospital Universitario Juan Ramón Jimenez, Gastroenterology Department, Huelva, Spain;(22)Hospital Universitario Virgen de La Victoria, Gastroenterology Department, Málaga, Spain;(23)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Gastroenterology Department, Galdakao, Spain;(24)La Fe University Hospital- Valencia: IISLaFe Investigación del Instituto de Investigación Sanitaria La Fe, Gastroenterology Department, Valencia, Spain;(25)Hospital Universitario de Cabueñes, Department of Gastroenterology, Gijón, Spain;(26)Hospital Universitario 12 de Octubre, Gastroenterology Department, Madrid, Spain;(27)Hospital Universitario Fundación Alcorcón, Gastroenterology Department, Madrid, Spain;(28)Hospital Univeristari Joan XXIII, Gastroenterology Department, Tarragona, Spain;(29)Hospital Universitario de Gran Canaria “Dr. Negrín”, Gastroenterology Department, Las Palmas de Gran Canaria, Spain;(30)Bioodonostia Health Research Institute - Donostia University Hospital- Universidad del País Vasco UPV/EHU- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, San Sebastián, Spain;(31)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Department, Ferrol, Spain;(32)Complexo Hospitalario Universitario de Ourense, Gastroenterology Department, Ourense, Spain;(33)Hospital Universitario de Torrejón. Universidad Francisco de Vitoria, Gastroenterology Department, Torrejón, Spain;(34)Hospital Clínico Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(35)Hospital General de Tomelloso. Instituto de Investigación Sanitaria Princesa. Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM and CIBEREHD, Gastroenterology Department, Tomelloso, Spain;(36)Hospital Clínico Universitario San Cecilio, Gastroenterology Department, Granada, Spain;(37)Hospital Universitari de Girona Trueta, Gastroenterology Department, Girona, Spain;on behalf of DUMBO study group of GETECCU
DOP81: Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trialECCO'24Year: 2024
Authors: Luu, K.(1);Dahl, M.(2);Hare, E.(2);Sibley, C.(1)*;Lizzul, P.(1);Randazzo, B.(1);
(1)AnaptysBio- Inc, Clinical, San Diego, United States;(2)AnaptysBio- Inc, Research, San Diego, United States;
DOP83: Intestinal epithelium-specific deletion of the Aryl hydrocarbon Receptor (AhR) reduces intestinal Tight Junction permeability thereby hindering homeostatic antigen sampling and tolerogenic immune responses.ECCO'24Year: 2024
Authors: Saha, K.(1)*;Ganapathy, A.S.(1);Arumugam, P.(1);Wang, A.(1);Harris, L.(2);Yochum, G.(2);Koltun, W.(2);Nighot, M.(1);Nighot, P.(1);
(1)Penn State College of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Hershey, United States;(2)Penn State College of Medicine, Division of colon and Rectal Surgery- Department of Surgery, Hershey, United States;